Core Viewpoint - The Gross Law Firm is notifying shareholders of Revance Therapeutics, Inc. about a class action lawsuit due to alleged misleading statements and material breaches related to a Distribution Agreement with Teoxane [1][2]. Group 1: Allegations - The complaint alleges that Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [1]. - The breach subjected the company to increased risks of litigation, monetary losses, and reputational harm [1]. - The allegations suggest that these issues increased the risk of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 29, 2024, to December 6, 2024 [1]. - Shareholders are encouraged to register for the class action by March 4, 2025, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case, and they will receive status updates through portfolio monitoring software [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=127843&from=4 CLASS PERIOD ...

NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/revance-therapeutics- ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=127269&from=4CLASS PERIOD: ...

NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the March 4, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) securities during the period from February 29, 2024, through December 6, 2024 (“the Class Period”). [LEARN MORE ABOUT THE CLASS ACTION] Prior to the Class Period, in January 2020, Revance entered in ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and Dece ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/revance-therapeutics- ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=126274&from=4CLASS PERIOD: ...

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Revance Therapeutics, Inc. (NASDAQ:RVNC). The lawsuit seeks to recover losses on behalf of investors who acquired securities between February 29, 2024 and December 6, 2024. Investors have until March 4, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit. If you incurred significant losses and want to act as the lead plaintiff in the Revance ...

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/revance-therapeutics ...